Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02499003 | GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma | PHASE2 | COMPLETED | 70 | — | — | Aug 14, 2015 | Jan 2, 2022 | Mar 31, 2022 | 1 | Germany |
The response to treatment is measured by results of computer tomography (CT) for measurable lesions and evaluation for non-measurable lesions after cycle 6 or at the individual end of treatment.
| Arm | Type | Description |
|---|---|---|
| Obinutuzumab and Pixantrone | EXPERIMENTAL | Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle |
| Name | Type | Description |
|---|---|---|
| Obinutuzumab and Pixantrone | DRUG | Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle |
Inclusion Criteria: * Patients aged ≥ 18 years * Histologically proven diagnosis of diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma (FL) IIIB or transformed indolent lymphoma according to the World Health Organization classification (central pathology review) * Relapsed disease * Ea...